Plicamycin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IV Hypercalcaemia and hypercalciuria associated w/ malignancy 25 mcg/kg. May repeat 24-72 hrly for several times. Paget's disease of bone 25 mcg/kg/day for 15 doses, followed by 1,500 mcg/wk for 2 mth, then 2 wkly for 6 wk.
Dosage Details
Intravenous
Paget's disease of bone
Adult: As 2nd or 3rd line of treatment: 25 mcg/kg/day by slow infusion for 15 doses followed by 1500 mcg wkly for 2 mth, then every 2 wk for 6 wk.

Intravenous
Hypercalcaemia and hypercalciuria associated with malignancy
Adult: 25 mcg/kg by slow infusion over 4-6 hr. May be repeated several times at intervals of 24-72 hr.
Contraindications
Pregnancy and lactation. Hypersensitivity.
Special Precautions
Impaired hepatic or renal function. Extravasation. Monitor CBC and electrolytes before each treatment; blood cell counts, coagulation time, hepatic and renal function frequently during treatment and several days after. Patients with coagulopathy.
Adverse Reactions
Dose-related bleeding syndrome, manifested initially as epistaxis. GI effects, metallic taste, mild stomatitis; fever, malaise, drowsiness, lethargy, weakness, headache, depression; skin rashes, facial flushing; reduced serum concentrations of calcium, phosphorus and potassium; reversible renal or hepatic impariment; transient elevated hepatic enzymes; extravasation may cause local irritation, cellulitis and phloebitis.
Potentially Fatal: Epitaxis progressing to haematemesis and fatal haemorrhage. Severe thrombocytopaenia due to bone marrow depression.
Drug Interactions
Admixture with trace element solutions. Chelates divalent cations eg iron.
Action
Description: Plicamycin, a highly toxic antibiotic with antineoplastic and hypocalcaemic properties, is cell-cycle phase-nonspecific that binds to DNA in the presence of divalent cations and inhibits synthesis of RNA. Its hypocalcaemic activity is due to blocking PTH action on osteoclasts.
Storage
Store at 2-8°C.
Disclaimer: This information is independently developed by MIMS based on Plicamycin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in